The Pfizer Covid vaccine increased the risk of heart problems for children sixfold in the first week of having the jab but ...

The Pfizer-BioNTech Covid-19 vaccine causes rare complications in children and young people, according to the study ...

The largest study of its kind has revealed that the Pfizer-BioNTech Covid-19 vaccine presents considerably fewer problems for ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

Pfizer’s sales of its COVID-19 vaccine, Comirnaty, fell sharply by 25% in the U.S. during the third quarter of 2025, dropping ...

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 ...

The study is the largest of its kind in this population, and is published in The Lancet Child and Adolescent Health.

Getting covid-19 for the first time slightly increased the risk of heart inflammation, blood clots and bleeding disorders among children, whereas being vaccinated against the virus was much safer and ...

Good day, everyone, and welcome to Pfizer's Third Quarter 2025 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief ...

But Pfizer (PFE) isn't going down without a fight. While Novo Nordisk's (NVO) bid could top Pfizer's by up to $2.7 billion, Pfizer Chief Executive Albert Bourla called it "illusory" and said it can't ...

Taking a closer look at the numbers, Comirnaty sales slipped 19% globally to $1.15 billion, the Prevnar franchise experienced a 3% global sales decline to $1.7 billion, and Abrysvo’s performance ...

The sales of Pfizer’s Comirnaty shots sank 25% after the U.S. government narrowed recommendations of who needs the jab ...